Immunotherapy

IF 2.5 3区医学 Q2 HEMATOLOGY

Hematology-Oncology Clinics of North America Pub Date : 2024-02-28 DOI:10.1016/j.hoc.2024.01.005

Layal Al Mahmasani MD , James J. Harding MD , Ghassan Abou-Alfa MD, MBA

引用次数: 0

查看原文本刊更多论文

免疫疗法：免疫疗法：胆道癌靶向治疗的急转弯

胆道癌症的发病率持续上升，死亡率也很高。大多数患者都是晚期患者。针对 IDH、FGFR、HER2、BRAFV600 E 等可靶向基因组改变的发现，促进了胆道癌新型疗法的确定和验证。最近的进展表明，在化疗中加入免疫检查点抑制剂可改善疗效，从而确立了新的一线治疗标准。如果存在使用检查点抑制剂的禁忌症和缺乏靶向性改变，化疗仍然是标准的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematology-Oncology Clinics of North America 医学-血液学

CiteScore

4.10

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Hematology/Oncology Clinics updates you on the latest trends in patient management, keeps you up to date on the newest advances, and provides a sound basis for choosing treatment options. Under the direction of an experienced guest editor, each issue focuses on a single topic in hematology and oncology, including hemostasis and thrombosis, molecular and cellular basis of hematology, coagulation disorders, and cancers—bone, gastrointestinal, head and neck, lymphomas, neuroendocrine, breast, renal cell, melanoma, and more.